Netherlands· NL-6b95b5f04d47
Spikevax bivalent origineel/omicron BA.1 (25 microgram/25 microgram) dispersie voor injectie in een voorgevulde spuit
A covid-19, rna-based vaccine product containing elasomeran + imelasomeran, registered in Netherlands by Moderna Biotech Spain S.L.. The same ATC class is registered in 11 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Covid-19, rna-based vaccine is registered in 11 of 19 countries.
Countries holding a registration under ATC J07BN01 (covid-19, rna-based vaccine), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Covid-19, rna-based vaccine · ATC J07BN01
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- ELASOMERAN + IMELASOMERAN
- Manufacturer
- Moderna Biotech Spain S.L.
- Country
- Netherlands (NL)
- ATC code
- J07BN01
- ATC class
- Covid-19, RNA-based vaccine
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/20/1507
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Covid-19, rna-based vaccine in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IcelandSpikevax bivalent Original/Omicron BA.1MODERNA BIOTECH SPAIN, S.L.
- SpainSPIKEVAX BIVALENTE ORIGINAL/OMICRON BA.1 (50 MICROGRAMOS/50 MICROGRAMOS)/ML DISPERSION INYECTABLEModerna Biotech Spain S.L.
- FranceSPIKEVAX BIVALENT ORIGINAL/OMICRON BA.1 (50 microgrammes/50 microgrammes)/ml, dispersion injectable, Vaccin à ARNm contre la COVID-19MODERNA BIOTECH SPAIN SL (ESPAGNE)
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e1e63180-b4d3-44e0-a643-9e4e7ac67f45 GET /v1/drugs/e1e63180-b4d3-44e0-a643-9e4e7ac67f45?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Dispersie voor injectie",
"route": "Intramusculair gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/spikevax-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Covid-19, RNA-based vaccine",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp131102",
"excipients": [
"1,2-DIMYRISTOYL-RAC-GLYCERO-3-METHOXYPOLYETHYLEENGLYCOL-2000",
"1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOCHOLINE",
"AZIJNZUUR (E 260)",
"CHOLESTEROL",
"HEPTADECAAN-9-YL 8-((2-HYDROXYETHYL)(6-OXO-6-(UNDECYLOXY) HEXYL) AMINO) OCTANOAAT",
"NATRIUMACETAAT 3-WATER (E 262)",
"SACCHAROSE",
"TROMETAMOL",
"TROMETAMOLHYDROCHLORIDE",
"WATER VOOR INJECTIE"
],
"substances": [
"ELASOMERAN",
"IMELASOMERAN"
],
"leaflet_url": null,
"authorised_at": "2021/01/06",
"procedure_number": "EMEA/H/C/005791",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/20/1507",
"additional_monitoring": "Y"
}See everything about covid-19, rna-based vaccine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.